Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics.
Sanofi completes acquisition of Amunix
February 9, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022